Neurolief

Neurolief is a neuromodulation medical device company specializing in non-invasive, FDA-approved brain stimulation systems for treating major depressive disorder (MDD), migraines, stress, and sleep disorders. The company's flagship product, Proliv™Rx, delivers combined occipital and trigeminal afferent stimulation (eCOT-AS) as a home-based, physician-directed adjunctive therapy for adults with treatment-resistant depression who have failed antidepressant medications. The system enables 8-16 week treatment programs delivered entirely at home with continuous clinician oversight and symptom tracking, eliminating the need for specialized clinic infrastructure, staffing burden, or geographic limitations. Clinical evidence demonstrates 87% of patients show improvement in depression severity with 96% treatment adherence. Proliv™Rx is FDA-approved in the USA, CE-marked in Europe, and PMDA-approved in Japan. The company also offers wearable neuromodulation devices including Relivion MG for acute and preventive migraine relief. All solutions leverage intelligent companion apps enabling remote patient monitoring and personalized treatment management outside traditional clinical settings.